Company news
Alterity Therapeutics Ltd. news in 2020
Alterity Therapeutics Ltd.'s news releases, calls and decks from 2020, newest first.
Form F-3
December 23, 2020
New commercial opportunity for PBT2
December 21, 2020
Alterity presents at Finance News Network
December 1, 2020
Prospectus filed pursuant to SEC Rule 424(b)(3)
November 24, 2020
Chairmans Address 2020 Annual General Meeting
November 17, 2020
US patent for next generation neurodegenerative diseases
November 15, 2020
MSA patients enrolled in bioMUSE Study
October 26, 2020
Alterity completes Placement Tranche 1 raising $10M
October 23, 2020
Alterity raises $35M in placement to institutional investors
October 15, 2020
Company update on Annual Report 2020
September 9, 2020
Preliminary Final Report
August 30, 2020
New data independently confirms safety profile of ATH434
August 4, 2020
Pause in Trading
July 1, 2020
Meeting with US FDA provides development path for ATH434
June 30, 2020
Presentation on ATH434 to American Academy of Neurology
May 20, 2020
Appendix 4C and Quarterly Update
April 30, 2020
NASDAQ Temporary Relief
April 22, 2020
NASDAQ Non-Compliance Notice Received
February 7, 2020
Appendix 4C - quarterly
January 31, 2020
Alterity receives a $4.8 million R&D Tax Incentive Refund
January 14, 2020
European Orphan Designation granted for PBT434 for MSA
January 13, 2020
Decks in 2020
- Finance News Network Investor Event (December 2020)
Conference · 12 slides · Dec 2, 2020
- Shareholder Meeting (November 2020)
Shareholder meeting · 27 slides · Nov 18, 2020